Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma.
BACKGROUND
Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen.Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test.


RESULTS
The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls (P < 0.02)


CONCLUSIONS
Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease.
Juranic
Zorica
Z
Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia. juranicz@ncrc.ac.yu
Radic
Jelena
J
Konic-Ristic
Aleksandra
A
Jelic
Svetislav
S
Mihaljevic
Biljana
B
Stankovic
Ivan
I
Matkovic
Suzana
S
Besu
Irina
I
Gavrilović
Dusica
D
D000328:Adult; D000906:Antibodies / Q000097:blood / Q000276:immunology; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019204:GTP-Binding Proteins / Q000276:immunology*; D005903:Gliadin / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000276:immunology* / Q000473:pathology; D009367:Neoplasm Staging; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012261:Ribonucleoproteins / Q000276:immunology*; D013223:Statistics as Topic; D011503:Transglutaminases / Q000276:immunology*; D000099207:SS-A Antigen
D000906:Antibodies; D019204:GTP-Binding Proteins; D005903:Gliadin; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012261:Ribonucleoproteins; D011503:Transglutaminases; D000099207:SS-A Antigen; C000717608:TGM2 protein, human